Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats

Chinese Medical Journal

Volumn 122, Issue 21, 2009, Pages 2573-2579

  Zhou, Hong ^a,b   Tian, Hao Ming ^a   Long, Yang ^a   Zhang, Xiang Xun ^a   Zhong, Li ^b   Deng, Li ^a   Chen, Xiao He ^a   Li, Xiu Qun ^a  

^a SICHUAN UNIVERSITY   (China)

^b The First People's Hospital of Longquanyi District   (China)

Author keywords

Ciclosporin A; Diabetic nephropathy; Mesenchymal stem cells; Urine albumin creatinine ratio

Indexed keywords

ALBUMIN; CREATININE; CYCLOSPORIN A; GLUCOSE;

ADIPOGENESIS; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL HOMING; CELL LABELING; CONTROLLED STUDY; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KIDNEY CELL; KIDNEY MASS; KIDNEY STRUCTURE; KIDNEY TUMOR; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PHENOTYPE; PROTEIN URINE LEVEL; RAT; STREPTOZOCIN DIABETES; URINALYSIS;

ANIMALS; BLOOD GLUCOSE; DIABETIC NEPHROPATHIES; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROSCOPY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 73449143871     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.21.009     Document Type: Article

References (32)

1. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346: 1145-1151.
2. Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. Am J Kidney Dis 2000; 35: 157-165.
3. Group UKPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
4. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576.
5. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
6. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
7. Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanism of diabetic nephropathy and its therapeutic intervention. Current Drug Targets 2007; 8: 952-959.
8. Prockop DJ. Marrow stromal cells as stem cells for non-hematopoietic tissues. Science 1997; 276: 71-74.
9. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
10. Digirolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ. Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with greatest potential to propagate and differentiate. Br J Haematol 1999; 107: 275-281.
11. Sanchez-Ramoz J, Song S, Cardozo-Pelaez F, Hazzi C, Stedeford T, Willing A, Freeman TB, et al. Adult bone marrow stromal cells differentiate into neuronal cells in vitro. Exp Neurol 2000; 164: 247-256.
12. Brazelton TR, Rossi FM, Keshet GI, Blau HM. From marrow to brain: expression of neuronal phenotype in adult mice. Science 2000; 290: 1775-1779.
13. Anglani F, Forino M, Del Prete D, Tosetto E, Torregrossa R, D'Angelo A. In search of adult renal stem cells. J Cell Mol Med 2004; 8: 474-487.
14. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289: 31-42.
15. Lange C, Togel F, Ittrich H, Clayton F, Nolte-Ernsting C, Zander AR, et al. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int 2005; 68: 1613-1617.
16. Kunter U, Rong S, Djuric Z, Boor P, Müller-Newen G, Yu D, et al. Transplanted mesenchymal stem cells accelerate glomerular healing in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17: 2202-2212.
17. Morigi M, Imberti B, Zoja C, Corna D, Tomasoni S, Abbate M, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004; 15: 1794-1804.
18. Ito T, Suzuki A, Imai E, Okabe M, Hori M. Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodeling. J Am Soc Nephrol 2001; 12: 2625-2635.
19. Poulsom R, Forbes SJ, Hodivala-Dilke K, Ryan E, Wyles S, Navaratnarasah S, et al. Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol 2001; 195: 229-235.
20. Gratzner HG. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982; 218: 474-475.
21. Kraynak AR, Storer RD, Jensen RD, Kloss MW, Soper KA, Clair JH, et al. Extent and persistence of streptozotocin-induced DNA damage and cell proliferation in rat kidney as determined by in vivo alkaline elution and BrdUrd labeling assays. Toxicol Appl Pharmacol 1995; 135: 279-286.
22. Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology (Carlton) 2007; 12: 261-266.
23. Imberti B, Morigi M, Tomasoni S, Rota C, Corna D, Longaretti L, et al. Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol 2007; 18: 2921-2928.
24. Bi B, Schmitt R, Israilova M, Nishio H, Cantley LG. Stromal cells protect against acute tubular injury via an endocrine effect. J Am Soc Nephrol 2007; 18: 2486-2496.
25. DuBose TD Jr, Warnock DG, Mehta RL, Bonventre JV, Hammerman MR, Molitoris BA, et al. Acute renal failure in the 21st century: recommendations for management and outcomes assessment. Am J Kidney Dis 1997; 29: 793-799.
26. Oliver JA, Maarouf O, Cheema FH, Martens TP, Al-Awqati Q. The renal papilla is a niche for adult kidney stem cells. J Clin Invest 2004; 114: 795-804.
27. Stagg J. Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens 2007; 69: 1-9.
28. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108: 2114-2120.
29. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I-and class II-mismatched recipient mice. Blood 2005; 106: 4057-4065.
30. Savikko J, Kallio EA, Taskinen E, von Willebrand E. The effect of acute rejection and cyclosporin A-treatment on induction of platelet-derived growth factor and its receptors during the development of chronic rat renal allograft rejection. Transplantation 2002; 73: 506-511.
31. Ninichuk V, Gross O, Segerer S, Hoffmann R, Radomska E, Buchstaller A, et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int 2006; 70: 121-129.
32. Mias C, Trouche E, Seguelas MH, Calcagno F, Dignat-George F, Sabatier F, et al. Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells 2008; 26: 1749-1757.